Loading...
Market
RYBREVANT and LAZCLUZE capture over 50% lung cancer treatment market share by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Market analysis reports from industry analysts
Story
Johnson & Johnson's RYBREVANT and LAZCLUZE Outperform Tagrisso, Promising Over One Year Survival Improvement Over Osimertinib
Jan 7, 2025, 01:11 PM
Johnson & Johnson announced that its lung cancer treatment, a combination of RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib), has shown a statistically significant and clinically meaningful improvement in overall survival compared to osimertinib. In a head-to-head study, this combination therapy outperformed AstraZeneca’s Tagrisso, which could potentially alter the standard of care for lung cancer, one of the most lethal tumor types. The company indicated that the median overall survival improvement is expected to exceed one year.
View original story
Similar markets
Less than 10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Leading • 25%
Lower • 25%
Third • 25%
Second • 25%
10% to 15% • 25%
5% to 10% • 25%
Less than 5% • 25%
More than 15% • 25%
Other • 25%
AstraZeneca/Daiichi Sankyo • 25%
Roche • 25%
Pfizer • 25%
No • 50%
Yes • 50%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
More than 60% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Enhertu (trastuzumab deruxtecan) • 25%
Other • 25%
Kisqali (ribociclib) • 25%
Verzenio (abemaciclib) • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
5% to 10% • 25%
Less than 5% • 25%
More than 15% • 25%
10% to 15% • 25%